Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$3.4 million.

  • Lineage Cell Therapeutics' Net Income towards Common Stockholders fell 1396.2% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year decrease of 5974.76%. This contributed to the annual value of -$18.6 million for FY2024, which is 1348.76% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$3.4 million for Q3 2025, which was down 1396.2% from -$19.3 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$1.4 million during Q1 2021, with a 5-year trough of -$28.0 million in Q4 2021.
  • For the 5-year period, Lineage Cell Therapeutics' Net Income towards Common Stockholders averaged around -$7.2 million, with its median value being -$6.0 million (2025).
  • The largest annual percentage gain for Lineage Cell Therapeutics' Net Income towards Common Stockholders in the last 5 years was 8281.92% (2021), contrasted with its biggest fall of 294644.31% (2021).
  • Over the past 5 years, Lineage Cell Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$28.0 million in 2021, then skyrocketed by 77.29% to -$6.4 million in 2022, then increased by 25.9% to -$4.7 million in 2023, then surged by 31.06% to -$3.2 million in 2024, then fell by 5.23% to -$3.4 million in 2025.
  • Its Net Income towards Common Stockholders was -$3.4 million in Q3 2025, compared to -$19.3 million in Q2 2025 and -$6.0 million in Q1 2025.